Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Single Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment.

Next Previous
Trial Profile

An Open Label, Single Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorcaserin (Primary)
  • Indications Obesity
  • Focus Pharmacokinetics
  • Sponsors Arena Pharmaceuticals; Eisai Inc

Most Recent Events

  • 29 Mar 2017 Results assessing pharmacokinetics and tolerability of Lorcaserin in different populations in three studies (NCT00828581, NCT00828438, and NCT00828932) published in the Clinical Therapeutics
  • 30 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 30 Jul 2009 Actual initiation date changed from Sep 2008 to Aug 2008 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top